Iovance Biotherapeutics
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 557
- Market Cap
- $3.4B
- Website
- http://www.iovance.com
- Introduction
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
- Conditions
- Unresectable MelanomaMetastatic MelanomaOcular Melanoma
- Interventions
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT06940739
- Locations
- πΊπΈ
SCRI Oncology Partners- Denver, Denver, Colorado, United States
πΊπΈSarah Cannon Research Institute, Nashville, Tennessee, United States
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
- Conditions
- RhabdomyosarcomaSoft Tissue SarcomaEwing SarcomaPrimary Central Nervous System CarcinomaMelanoma
- Interventions
- Biological: LN-145/LN-144
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06566092
- Locations
- πΊπΈ
Children's Hospital of Colorado, Aurora, Colorado, United States
πΊπΈRoswell Park Cancer Institute, Buffalo, New York, United States
πΊπΈJohns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06481592
- Locations
- πΊπΈ
H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, Florida, United States
πΊπΈAvera Medical Group Oncology, Sioux Falls, South Dakota, United States
πΊπΈUniversity of Southern California, Los Angeles, California, United States
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
- Conditions
- MelanomaUnresectable MelanomaMetastatic Melanoma
- Interventions
- First Posted Date
- 2023-02-14
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 670
- Registration Number
- NCT05727904
- Locations
- πΊπΈ
University of Alabama at Birmingham: The Kirklin Clinic, Birmingham, Alabama, United States
πΊπΈCity of Hope, Duarte, California, United States
πΊπΈUSC Norris Comprehensive Cancer Center, Los Angeles, California, United States
Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release
- Conditions
- Unresectable MelanomaMetastatic Melanoma
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Registration Number
- NCT05398640
- Locations
- πΊπΈ
HonorHealth, Scottsdale, Arizona, United States
πΊπΈCity of Hope, Duarte, California, United States
πΊπΈStanford Hospital, Stanford, California, United States
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
- Conditions
- Unresectable MelanomaStage III Non-small Cell Lung CancerMetastatic MelanomaStage IV Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-05-04
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT05361174
- Locations
- πΊπΈ
The Angeles Clinic and Research Institute, Los Angeles, California, United States
πΊπΈSylvester Comprehensive Cancer Center, Miami, Florida, United States
πΊπΈOrlando Health Cancer Institute, Orlando, Florida, United States
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 170
- Registration Number
- NCT04614103
- Locations
- πΊπΈ
City of Hope, Duarte, California, United States
πΊπΈUC San Diego Moores Cancer Center, La Jolla, California, United States
πΊπΈUniversity of Southern California, Los Angeles, California, United States
Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT04155710
- Locations
- πΊπΈ
Duke University, Durham, North Carolina, United States
πΊπΈUniversity of Cincinnati Medical Center, Cincinnati, Ohio, United States
πΊπΈBaptist Cancer Center, Memphis, Tennessee, United States
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
- Conditions
- Squamous Cell Carcinoma of the Head and NeckMetastatic MelanomaNon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 245
- Registration Number
- NCT03645928
- Locations
- πΊπΈ
University of California, San Diego, La Jolla, California, United States
πΊπΈUniversity of Southern California, Los Angeles, California, United States
πΊπΈUniversity of California, Los Angeles, Los Angeles, California, United States
Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Registration Number
- NCT03419559
- Locations
- πΊπΈ
University of California San Diego, Moores Cancer Center, La Jolla, California, United States
πΊπΈUniversity of California, Los Angeles, Santa Monica Hematology/Oncology, Los Angeles, California, United States
πΊπΈUniversity of Louisville James Graham Brown Cancer Center, Louisville, Kentucky, United States